Anavex Life Sciences Corp (AVXL)

[falconer66a]

Successful Anavex 3-71 Dosage Against Murine Alzheimer’s

In this study, of transgenic (Tg) rats with human Alzheimer’s genes (and disease), Anavex 3-71 (AF710B) was dosed at a rate of 10 µg/kg per day, orally administered. At that tiny dose Anavex 3-71 produced reversion of cognitive deficits of the disease --- a therapeutic success.

https://www.researchgate.net/publication/322142767_AF710B_an_M1sigma-1_receptor_agonist_with_long-lasting_disease-modifying_properties_in_a_transgenic_rat_model_of_Alzheimer's_disease

Here’s an excerpt:

Chronic treatment with AF710B [Anavex 3-71] (10 µg/kg) was initiated in postplaque 13-month-old Tg rats. Drug or vehicle was administered orally daily for 4.5 months and interrupted 5 weeks before behavioral testing. Results: AF710B long-term treatment reverted the cognitive deficits associated with advanced Alzheimer-like amyloid neuropathology in Tg rats.

One microgram (µg) is one millionth of a gram. At this dosage, a 150lb human (weighing 68 kg) with Alzheimer's would take 680 µg, 0.68 milligrams, each day. Less than a single milligram. By any measure, that’s very fractional compared to the many milligram doses of Anavex 2-73 (blarcamesine) being used in human clinical trials.

The research was reported in Alzheimer's & dementia: the journal of the Alzheimer's Association. It's "scientific."